chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Laboratory test, Ocular hyperaemia, Oculorespiratory syndrome, Oropharyngeal pain, Tachycardia
Clinical narrative: This case was extracted from the database via QScan on 11 March 2009 (reference number 265693). A 26-year-old female patient, who has no allergy to eggs or eggs products, had received on 30 October 2006 at 12:00 pm a first intramuscular injection of FLUZONE SV 2005-2006 USP (lot number U2212AA). Approximately two hours and fifty-five minutes after receiving the vaccination, which was around 14:55 pm, the patient began to have some symptoms (types of symptoms were not reported). She subsequently presented to the emergency room two hours and forty-five minutes later, which was around 17:40 pm, with tachycardia, eye redness, and an itchy sore throat. The patient was treated with intravenous SOLU-MEDROL and BENADRYL; and received one breathing treatment. The indication for the breathing treatment was not reported. The patient was observed until 02:00 am the following morning and was discharged. Relevant diagnostic tests and laboratory data performed were not reported. Final diagnosis was Oculo-Respiratory syndrome. The patient recovered (date not reported). The patient was diagnosed with Oculo-Respiratory syndrome; however the agency did not code this as an event. Documents held by Sender: None.
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Throat irritation
Clinical narrative: This case was extracted from the database via QScan on 11 March 2009 (reference number 265693). A 26-year-old female patient, who has no allergy to eggs or eggs products, had received on 30 October 2006 at 12:00 pm a first intramuscular injection of FLUZONE SV 2005-2006 USP (lot number U2212AA). Approximately two hours and fifty-five minutes after receiving the vaccination, which was around 14:55 pm, the patient began to have some symptoms (types of symptoms were not reported). She subsequently presented to the emergency room two hours and forty-five minutes later, which was around 17:40 pm, with tachycardia, eye redness, and an itchy sore throat. The patient was treated with intravenous SOLU-MEDROL and BENADRYL; and received one breathing treatment. The indication for the breathing treatment was not reported. The patient was observed until 02:00 am the following morning and was discharged. Relevant diagnostic tests and laboratory data performed were not reported. Final diagnosis was Oculo-Respiratory syndrome. The patient recovered (date not reported). The patient was diagnosed with Oculo-Respiratory syndrome; however the agency did not code this as an event. Documents held by Sender: None.
Age: 30.0
Sex: F
Vaccine: FLU3
Symptoms: Chest discomfort, Dizziness, Face oedema, Hyperhidrosis, Lip swelling
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 265736). A 30-year-old female patient had received a first dose intramuscular injection of FLUZONE SV 2006-2007 USP, lot number U2244AA on 31 October 2006 and on the day of vaccination, she experienced dizziness, diaphoresis, chest tightness, hives on her torso, itching, throat tightness, swollen lips and bloodshot eyes. She received corrective treatment with BENADRYL and PREDNISONE and subsequently recovered (date of recovery not reported). The event of face oedema was included in the coding from the VAERS database; however was not mentioned in the narrative.
Age: 30.0
Sex: F
Vaccine: FLU3
Symptoms: Ocular hyperaemia, Pruritus, Throat tightness, Urticaria
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 265736). A 30-year-old female patient had received a first dose intramuscular injection of FLUZONE SV 2006-2007 USP, lot number U2244AA on 31 October 2006 and on the day of vaccination, she experienced dizziness, diaphoresis, chest tightness, hives on her torso, itching, throat tightness, swollen lips and bloodshot eyes. She received corrective treatment with BENADRYL and PREDNISONE and subsequently recovered (date of recovery not reported). The event of face oedema was included in the coding from the VAERS database; however was not mentioned in the narrative.
Age: 21.0
Sex: F
Vaccine: FLU3
Symptoms: Blood potassium decreased, Chest pain, Dyspnoea, Eye swelling, Hypotension
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 267106). A 21 year old female patient received a first time dose of FLUZONE (lot number U2177AA) intramuscularly on 10 October 2006 around 1:00 PM. During the evening of vaccination, the patient developed shortness of breath, red and swollen eyes, a rash on her neck and chest, hypotension, tachycardia, and chest pain. The patient was treated in the emergency room for possible allergic reaction to the flu vaccine. Labs included "DD QNT 957" and potassium 3.1 on 10 October 2006 and WBC 14.9 on 11 October 2006. The patient's recovery status was not reported. List of documents held by sender: none.
Age: 21.0
Sex: F
Vaccine: FLU3
Symptoms: Laboratory test, Ocular hyperaemia, Rash, Tachycardia, White blood cell count increased
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 267106). A 21 year old female patient received a first time dose of FLUZONE (lot number U2177AA) intramuscularly on 10 October 2006 around 1:00 PM. During the evening of vaccination, the patient developed shortness of breath, red and swollen eyes, a rash on her neck and chest, hypotension, tachycardia, and chest pain. The patient was treated in the emergency room for possible allergic reaction to the flu vaccine. Labs included "DD QNT 957" and potassium 3.1 on 10 October 2006 and WBC 14.9 on 11 October 2006. The patient's recovery status was not reported. List of documents held by sender: none.
Age: 39.0
Sex: F
Vaccine: FLU3
Symptoms: Anxiety, Blood glucose abnormal, Blood urea decreased, Cardiac enzymes normal, Chest X-ray normal
Clinical narrative: This case was extracted from the VAERS database via QScan on 11 March 2009 (identification number 273122). A 39-year-old female patient, who has no history of allergy to eggs, but does have allergy to SUDAFED, had received on 02 February 2007 at 15:00 pm a first intramuscular injection of FLUZONE SV 2006-2007 USP (lot number U2240AA, site of administration not reported). Around 16:50 pm, the patient complained of extreme itching  (site not reported) and SOB. Around 17:05 pm, the patient reported increased itching and swelling around her eyes. Her eyes were red and puffy. The patient was administered a 0.5 mL subcutaneous dose of Epinephrine 1:1000, Albuterol, intravenous BENADRYL 50 mg, and four doses of SOLU-MEDROL 125 mg. VAERS received medical records on 06 March 2007 and it was noted the patient was hospitalized for complaint of chest pain and dyspnea following her flu shot. En route to the hospital on 02 February 2007, the patient was treated with four baby ASA (aspirin), sublingual nitroglycerine and oxygen via NC (nasal cannula). She also experienced circumoral paresthesia and numbness down her left arm secondary to hyperventilation, as she became increasingly panicked. Physical examination revealed urticaria on the face and abdomen and periorbital swelling. The patient was anxious, but otherwise within normal limits. Assessment was chest pain that appeared to be chest wall tenderness, dyspnea, hyperventilation and acute allergic reaction probably to the flu vaccine. Diagnostic tests and laboratory data revealed negative cardiac enzymes, negative D-dimer test, normal chest x-ray, NSR on an EKG, BUN 5, CMP that showed glucose of 142 (due to being on steroids) and CBC was unremarkable. The final diagnosis was acute allergic reaction likely due to flu vaccine serum. The patient recovered (date not reported). Documents held by sender: None.
Age: 39.0
Sex: F
Vaccine: FLU3
Symptoms: Chest pain, Dyspnoea, Electrocardiogram normal, Eye swelling, Fibrin D dimer normal
Clinical narrative: This case was extracted from the VAERS database via QScan on 11 March 2009 (identification number 273122). A 39-year-old female patient, who has no history of allergy to eggs, but does have allergy to SUDAFED, had received on 02 February 2007 at 15:00 pm a first intramuscular injection of FLUZONE SV 2006-2007 USP (lot number U2240AA, site of administration not reported). Around 16:50 pm, the patient complained of extreme itching  (site not reported) and SOB. Around 17:05 pm, the patient reported increased itching and swelling around her eyes. Her eyes were red and puffy. The patient was administered a 0.5 mL subcutaneous dose of Epinephrine 1:1000, Albuterol, intravenous BENADRYL 50 mg, and four doses of SOLU-MEDROL 125 mg. VAERS received medical records on 06 March 2007 and it was noted the patient was hospitalized for complaint of chest pain and dyspnea following her flu shot. En route to the hospital on 02 February 2007, the patient was treated with four baby ASA (aspirin), sublingual nitroglycerine and oxygen via NC (nasal cannula). She also experienced circumoral paresthesia and numbness down her left arm secondary to hyperventilation, as she became increasingly panicked. Physical examination revealed urticaria on the face and abdomen and periorbital swelling. The patient was anxious, but otherwise within normal limits. Assessment was chest pain that appeared to be chest wall tenderness, dyspnea, hyperventilation and acute allergic reaction probably to the flu vaccine. Diagnostic tests and laboratory data revealed negative cardiac enzymes, negative D-dimer test, normal chest x-ray, NSR on an EKG, BUN 5, CMP that showed glucose of 142 (due to being on steroids) and CBC was unremarkable. The final diagnosis was acute allergic reaction likely due to flu vaccine serum. The patient recovered (date not reported). Documents held by sender: None.
Age: 39.0
Sex: F
Vaccine: FLU3
Symptoms: Full blood count normal, Hypersensitivity, Hyperventilation, Hypoaesthesia, Musculoskeletal chest pain
Clinical narrative: This case was extracted from the VAERS database via QScan on 11 March 2009 (identification number 273122). A 39-year-old female patient, who has no history of allergy to eggs, but does have allergy to SUDAFED, had received on 02 February 2007 at 15:00 pm a first intramuscular injection of FLUZONE SV 2006-2007 USP (lot number U2240AA, site of administration not reported). Around 16:50 pm, the patient complained of extreme itching  (site not reported) and SOB. Around 17:05 pm, the patient reported increased itching and swelling around her eyes. Her eyes were red and puffy. The patient was administered a 0.5 mL subcutaneous dose of Epinephrine 1:1000, Albuterol, intravenous BENADRYL 50 mg, and four doses of SOLU-MEDROL 125 mg. VAERS received medical records on 06 March 2007 and it was noted the patient was hospitalized for complaint of chest pain and dyspnea following her flu shot. En route to the hospital on 02 February 2007, the patient was treated with four baby ASA (aspirin), sublingual nitroglycerine and oxygen via NC (nasal cannula). She also experienced circumoral paresthesia and numbness down her left arm secondary to hyperventilation, as she became increasingly panicked. Physical examination revealed urticaria on the face and abdomen and periorbital swelling. The patient was anxious, but otherwise within normal limits. Assessment was chest pain that appeared to be chest wall tenderness, dyspnea, hyperventilation and acute allergic reaction probably to the flu vaccine. Diagnostic tests and laboratory data revealed negative cardiac enzymes, negative D-dimer test, normal chest x-ray, NSR on an EKG, BUN 5, CMP that showed glucose of 142 (due to being on steroids) and CBC was unremarkable. The final diagnosis was acute allergic reaction likely due to flu vaccine serum. The patient recovered (date not reported). Documents held by sender: None.
Age: 39.0
Sex: F
Vaccine: FLU3
Symptoms: Ocular hyperaemia, Oxygen supplementation, Panic reaction, Paraesthesia oral, Pruritus
Clinical narrative: This case was extracted from the VAERS database via QScan on 11 March 2009 (identification number 273122). A 39-year-old female patient, who has no history of allergy to eggs, but does have allergy to SUDAFED, had received on 02 February 2007 at 15:00 pm a first intramuscular injection of FLUZONE SV 2006-2007 USP (lot number U2240AA, site of administration not reported). Around 16:50 pm, the patient complained of extreme itching  (site not reported) and SOB. Around 17:05 pm, the patient reported increased itching and swelling around her eyes. Her eyes were red and puffy. The patient was administered a 0.5 mL subcutaneous dose of Epinephrine 1:1000, Albuterol, intravenous BENADRYL 50 mg, and four doses of SOLU-MEDROL 125 mg. VAERS received medical records on 06 March 2007 and it was noted the patient was hospitalized for complaint of chest pain and dyspnea following her flu shot. En route to the hospital on 02 February 2007, the patient was treated with four baby ASA (aspirin), sublingual nitroglycerine and oxygen via NC (nasal cannula). She also experienced circumoral paresthesia and numbness down her left arm secondary to hyperventilation, as she became increasingly panicked. Physical examination revealed urticaria on the face and abdomen and periorbital swelling. The patient was anxious, but otherwise within normal limits. Assessment was chest pain that appeared to be chest wall tenderness, dyspnea, hyperventilation and acute allergic reaction probably to the flu vaccine. Diagnostic tests and laboratory data revealed negative cardiac enzymes, negative D-dimer test, normal chest x-ray, NSR on an EKG, BUN 5, CMP that showed glucose of 142 (due to being on steroids) and CBC was unremarkable. The final diagnosis was acute allergic reaction likely due to flu vaccine serum. The patient recovered (date not reported). Documents held by sender: None.
Age: 39.0
Sex: F
Vaccine: FLU3
Symptoms: Swelling, Urticaria
Clinical narrative: This case was extracted from the VAERS database via QScan on 11 March 2009 (identification number 273122). A 39-year-old female patient, who has no history of allergy to eggs, but does have allergy to SUDAFED, had received on 02 February 2007 at 15:00 pm a first intramuscular injection of FLUZONE SV 2006-2007 USP (lot number U2240AA, site of administration not reported). Around 16:50 pm, the patient complained of extreme itching  (site not reported) and SOB. Around 17:05 pm, the patient reported increased itching and swelling around her eyes. Her eyes were red and puffy. The patient was administered a 0.5 mL subcutaneous dose of Epinephrine 1:1000, Albuterol, intravenous BENADRYL 50 mg, and four doses of SOLU-MEDROL 125 mg. VAERS received medical records on 06 March 2007 and it was noted the patient was hospitalized for complaint of chest pain and dyspnea following her flu shot. En route to the hospital on 02 February 2007, the patient was treated with four baby ASA (aspirin), sublingual nitroglycerine and oxygen via NC (nasal cannula). She also experienced circumoral paresthesia and numbness down her left arm secondary to hyperventilation, as she became increasingly panicked. Physical examination revealed urticaria on the face and abdomen and periorbital swelling. The patient was anxious, but otherwise within normal limits. Assessment was chest pain that appeared to be chest wall tenderness, dyspnea, hyperventilation and acute allergic reaction probably to the flu vaccine. Diagnostic tests and laboratory data revealed negative cardiac enzymes, negative D-dimer test, normal chest x-ray, NSR on an EKG, BUN 5, CMP that showed glucose of 142 (due to being on steroids) and CBC was unremarkable. The final diagnosis was acute allergic reaction likely due to flu vaccine serum. The patient recovered (date not reported). Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: DTAP, FLU3, HEPA, PNC, DTAP, FLU3, HEPA, PNC
Symptoms: Asthma, Blood culture negative, Body temperature increased, Bronchitis, Chest X-ray normal
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (VAERS identification number 277174). A two-year-old female patient whose medical history was not reported, had received on 29 December 2006 a first intramuscular injection of FLUZONE No Preservative (lot number U2191CA); a third intramuscular injection of TRIPEDIA (lot number U1857CA); a first intramuscular injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB130AA); and a third intramuscular injection of PREVNAR (Manufacturer Wyeth, lot number B08657C). The sites of administrations were not reported for any of the vaccines. Around 20:00 pm or 21:00 pm on 29 December 2006, the patient developed a temperature of 102.4 degrees Fahrenheit and was irritable. Approximately seven days later, she experienced a severe diffuse cough and she had an earache, nausea and vomiting. The patient had been evaluated by a physician (date not reported) and was treated with nebulizer treatments on an outpatient basis without improvement. On 08 January 2007 the patient was hospitalized and diagnosed with flu and bronchitis. Temperature on admission was 100.8 degrees Fahrenheit and physical examination revealed a respiratory rate of 32 breaths per minute with wheezing and rhonchi in the lung fields. The patient was treated with intravenous antibiotics and nebulizer treatments. It was noted the patient was also treated for bacterial appearing conjunctivitis. Diagnostic tests included a viral wash that was positive for influenza Type B, a negative RSV (respiratory syncytial virus) test, a sedimentation rate (SED rate) of 28, a CBC (complete blood count) that had a left shift, a negative blood culture and sensitivity test, and a negative chest x-ray. The patient experienced resolution of the wheezing at the time of discharge, but the cough continued. The patient was discharged on day four of hospitalization which was on 11 January 2007. At that time, the patient was discharged on continued nebulizer treatments, cough medications and oral antibiotics. Final diagnosis at discharge was community-acquired pneumonia, allergic "bronchoasthma", respiratory distress, conjunctivitis, and acute influenza Type B. The patient recovered (date not reported). Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: DTAP, FLU3, HEPA, PNC, DTAP, FLU3, HEPA, PNC
Symptoms: Conjunctivitis, Cough, Ear pain, Full blood count abnormal, Influenza
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (VAERS identification number 277174). A two-year-old female patient whose medical history was not reported, had received on 29 December 2006 a first intramuscular injection of FLUZONE No Preservative (lot number U2191CA); a third intramuscular injection of TRIPEDIA (lot number U1857CA); a first intramuscular injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB130AA); and a third intramuscular injection of PREVNAR (Manufacturer Wyeth, lot number B08657C). The sites of administrations were not reported for any of the vaccines. Around 20:00 pm or 21:00 pm on 29 December 2006, the patient developed a temperature of 102.4 degrees Fahrenheit and was irritable. Approximately seven days later, she experienced a severe diffuse cough and she had an earache, nausea and vomiting. The patient had been evaluated by a physician (date not reported) and was treated with nebulizer treatments on an outpatient basis without improvement. On 08 January 2007 the patient was hospitalized and diagnosed with flu and bronchitis. Temperature on admission was 100.8 degrees Fahrenheit and physical examination revealed a respiratory rate of 32 breaths per minute with wheezing and rhonchi in the lung fields. The patient was treated with intravenous antibiotics and nebulizer treatments. It was noted the patient was also treated for bacterial appearing conjunctivitis. Diagnostic tests included a viral wash that was positive for influenza Type B, a negative RSV (respiratory syncytial virus) test, a sedimentation rate (SED rate) of 28, a CBC (complete blood count) that had a left shift, a negative blood culture and sensitivity test, and a negative chest x-ray. The patient experienced resolution of the wheezing at the time of discharge, but the cough continued. The patient was discharged on day four of hospitalization which was on 11 January 2007. At that time, the patient was discharged on continued nebulizer treatments, cough medications and oral antibiotics. Final diagnosis at discharge was community-acquired pneumonia, allergic "bronchoasthma", respiratory distress, conjunctivitis, and acute influenza Type B. The patient recovered (date not reported). Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: DTAP, FLU3, HEPA, PNC, DTAP, FLU3, HEPA, PNC
Symptoms: Influenza serology positive, Irritability, Nausea, Pneumonia, Red blood cell sedimentation rate increased
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (VAERS identification number 277174). A two-year-old female patient whose medical history was not reported, had received on 29 December 2006 a first intramuscular injection of FLUZONE No Preservative (lot number U2191CA); a third intramuscular injection of TRIPEDIA (lot number U1857CA); a first intramuscular injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB130AA); and a third intramuscular injection of PREVNAR (Manufacturer Wyeth, lot number B08657C). The sites of administrations were not reported for any of the vaccines. Around 20:00 pm or 21:00 pm on 29 December 2006, the patient developed a temperature of 102.4 degrees Fahrenheit and was irritable. Approximately seven days later, she experienced a severe diffuse cough and she had an earache, nausea and vomiting. The patient had been evaluated by a physician (date not reported) and was treated with nebulizer treatments on an outpatient basis without improvement. On 08 January 2007 the patient was hospitalized and diagnosed with flu and bronchitis. Temperature on admission was 100.8 degrees Fahrenheit and physical examination revealed a respiratory rate of 32 breaths per minute with wheezing and rhonchi in the lung fields. The patient was treated with intravenous antibiotics and nebulizer treatments. It was noted the patient was also treated for bacterial appearing conjunctivitis. Diagnostic tests included a viral wash that was positive for influenza Type B, a negative RSV (respiratory syncytial virus) test, a sedimentation rate (SED rate) of 28, a CBC (complete blood count) that had a left shift, a negative blood culture and sensitivity test, and a negative chest x-ray. The patient experienced resolution of the wheezing at the time of discharge, but the cough continued. The patient was discharged on day four of hospitalization which was on 11 January 2007. At that time, the patient was discharged on continued nebulizer treatments, cough medications and oral antibiotics. Final diagnosis at discharge was community-acquired pneumonia, allergic "bronchoasthma", respiratory distress, conjunctivitis, and acute influenza Type B. The patient recovered (date not reported). Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: DTAP, FLU3, HEPA, PNC, DTAP, FLU3, HEPA, PNC
Symptoms: Respiratory distress, Respiratory syncytial virus test negative, Rhonchi, Viral test positive, Vomiting
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (VAERS identification number 277174). A two-year-old female patient whose medical history was not reported, had received on 29 December 2006 a first intramuscular injection of FLUZONE No Preservative (lot number U2191CA); a third intramuscular injection of TRIPEDIA (lot number U1857CA); a first intramuscular injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB130AA); and a third intramuscular injection of PREVNAR (Manufacturer Wyeth, lot number B08657C). The sites of administrations were not reported for any of the vaccines. Around 20:00 pm or 21:00 pm on 29 December 2006, the patient developed a temperature of 102.4 degrees Fahrenheit and was irritable. Approximately seven days later, she experienced a severe diffuse cough and she had an earache, nausea and vomiting. The patient had been evaluated by a physician (date not reported) and was treated with nebulizer treatments on an outpatient basis without improvement. On 08 January 2007 the patient was hospitalized and diagnosed with flu and bronchitis. Temperature on admission was 100.8 degrees Fahrenheit and physical examination revealed a respiratory rate of 32 breaths per minute with wheezing and rhonchi in the lung fields. The patient was treated with intravenous antibiotics and nebulizer treatments. It was noted the patient was also treated for bacterial appearing conjunctivitis. Diagnostic tests included a viral wash that was positive for influenza Type B, a negative RSV (respiratory syncytial virus) test, a sedimentation rate (SED rate) of 28, a CBC (complete blood count) that had a left shift, a negative blood culture and sensitivity test, and a negative chest x-ray. The patient experienced resolution of the wheezing at the time of discharge, but the cough continued. The patient was discharged on day four of hospitalization which was on 11 January 2007. At that time, the patient was discharged on continued nebulizer treatments, cough medications and oral antibiotics. Final diagnosis at discharge was community-acquired pneumonia, allergic "bronchoasthma", respiratory distress, conjunctivitis, and acute influenza Type B. The patient recovered (date not reported). Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: DTAP, FLU3, HEPA, PNC, DTAP, FLU3, HEPA, PNC
Symptoms: Wheezing
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (VAERS identification number 277174). A two-year-old female patient whose medical history was not reported, had received on 29 December 2006 a first intramuscular injection of FLUZONE No Preservative (lot number U2191CA); a third intramuscular injection of TRIPEDIA (lot number U1857CA); a first intramuscular injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB130AA); and a third intramuscular injection of PREVNAR (Manufacturer Wyeth, lot number B08657C). The sites of administrations were not reported for any of the vaccines. Around 20:00 pm or 21:00 pm on 29 December 2006, the patient developed a temperature of 102.4 degrees Fahrenheit and was irritable. Approximately seven days later, she experienced a severe diffuse cough and she had an earache, nausea and vomiting. The patient had been evaluated by a physician (date not reported) and was treated with nebulizer treatments on an outpatient basis without improvement. On 08 January 2007 the patient was hospitalized and diagnosed with flu and bronchitis. Temperature on admission was 100.8 degrees Fahrenheit and physical examination revealed a respiratory rate of 32 breaths per minute with wheezing and rhonchi in the lung fields. The patient was treated with intravenous antibiotics and nebulizer treatments. It was noted the patient was also treated for bacterial appearing conjunctivitis. Diagnostic tests included a viral wash that was positive for influenza Type B, a negative RSV (respiratory syncytial virus) test, a sedimentation rate (SED rate) of 28, a CBC (complete blood count) that had a left shift, a negative blood culture and sensitivity test, and a negative chest x-ray. The patient experienced resolution of the wheezing at the time of discharge, but the cough continued. The patient was discharged on day four of hospitalization which was on 11 January 2007. At that time, the patient was discharged on continued nebulizer treatments, cough medications and oral antibiotics. Final diagnosis at discharge was community-acquired pneumonia, allergic "bronchoasthma", respiratory distress, conjunctivitis, and acute influenza Type B. The patient recovered (date not reported). Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: DTAP, FLU3, HEPA, PNC, DTAP, FLU3, HEPA, PNC
Symptoms: Respiratory distress, Respiratory syncytial virus test negative, Rhonchi, Vomiting, Wheezing
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (VAERS identification number 277174). A two-year-old female patient whose medical history was not reported, had received on 29 December 2006 a first intramuscular injection of FLUZONE No Preservative (lot number U2191CA); a third intramuscular injection of TRIPEDIA (lot number U1857CA); a first intramuscular injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB130AA); and a third intramuscular injection of PREVNAR (Manufacturer Wyeth, lot number B08657C). The sites of administrations were not reported for any of the vaccines. Around 20:00 pm or 21:00 pm on 29 December 2006, the patient developed a temperature of 102.4 degrees Fahrenheit and was irritable. Approximately seven days later, she experienced a severe diffuse cough and she had an earache, nausea and vomiting. The patient had been evaluated by a physician (date not reported) and was treated with nebulizer treatments on an outpatient basis without improvement. On 08 January 2007 the patient was hospitalized and diagnosed with flu and bronchitis. Temperature on admission was 100.8 degrees Fahrenheit and physical examination revealed a respiratory rate of 32 breaths per minute with wheezing and rhonchi in the lung fields. The patient was treated with intravenous antibiotics and nebulizer treatments. It was noted the patient was also treated for bacterial appearing conjunctivitis. Diagnostic tests included a viral wash that was positive for influenza Type B, a negative RSV (respiratory syncytial virus) test, a sedimentation rate (SED rate) of 28, a CBC (complete blood count) that had a left shift, a negative blood culture and sensitivity test, and a negative chest x-ray. The patient experienced resolution of the wheezing at the time of discharge, but the cough continued. The patient was discharged on day four of hospitalization which was on 11 January 2007. At that time, the patient was discharged on continued nebulizer treatments, cough medications and oral antibiotics. Final diagnosis at discharge was community-acquired pneumonia, allergic "bronchoasthma", respiratory distress, conjunctivitis, and acute influenza Type B. The patient recovered (date not reported). Documents held by sender: None.
Age: 38.0
Sex: F
Vaccine: FLU3
Symptoms: Abdominal discomfort, Adverse drug reaction, Chest X-ray, Chest discomfort, Chills
Clinical narrative: This case was extracted from VAERS via QSCAN on 11 March 2009 (reference number 293833). A 38-year-old female patient received an intramuscular injection of FLUZONE SV 2007-2008 (lot number U2505AA) on 15 October 2007. Approximately five hours post-vaccination, the patient complained of shortness of breath, lightheadedness, a sick feeling in her stomach, and a "racing heart". She experienced a cough, dry heaves, blood-shot eyes with pus, profuse sweating, and shivering. The symptoms continued the next morning, and at that time she also complained of eye and cheek swelling, and lightheadedness. She was unable to take a deep breath, and felt like "something was in my lungs". She was advised by her physician to go to the emergency room, where she underwent laboratory testing and a chest x-ray (results not provided). She was also started on an IV. According to the patient, the discharge diagnosis was "unspecified adverse effect of other drug, medicinal and biological substance". The event subsequently recovered.
Age: 38.0
Sex: F
Vaccine: FLU3
Symptoms: Cough, Dizziness, Dyspnoea, Eye discharge, Eye swelling
Clinical narrative: This case was extracted from VAERS via QSCAN on 11 March 2009 (reference number 293833). A 38-year-old female patient received an intramuscular injection of FLUZONE SV 2007-2008 (lot number U2505AA) on 15 October 2007. Approximately five hours post-vaccination, the patient complained of shortness of breath, lightheadedness, a sick feeling in her stomach, and a "racing heart". She experienced a cough, dry heaves, blood-shot eyes with pus, profuse sweating, and shivering. The symptoms continued the next morning, and at that time she also complained of eye and cheek swelling, and lightheadedness. She was unable to take a deep breath, and felt like "something was in my lungs". She was advised by her physician to go to the emergency room, where she underwent laboratory testing and a chest x-ray (results not provided). She was also started on an IV. According to the patient, the discharge diagnosis was "unspecified adverse effect of other drug, medicinal and biological substance". The event subsequently recovered.
Age: 38.0
Sex: F
Vaccine: FLU3
Symptoms: Fluid replacement, Hyperhidrosis, Laboratory test, Malaise, Ocular hyperaemia
Clinical narrative: This case was extracted from VAERS via QSCAN on 11 March 2009 (reference number 293833). A 38-year-old female patient received an intramuscular injection of FLUZONE SV 2007-2008 (lot number U2505AA) on 15 October 2007. Approximately five hours post-vaccination, the patient complained of shortness of breath, lightheadedness, a sick feeling in her stomach, and a "racing heart". She experienced a cough, dry heaves, blood-shot eyes with pus, profuse sweating, and shivering. The symptoms continued the next morning, and at that time she also complained of eye and cheek swelling, and lightheadedness. She was unable to take a deep breath, and felt like "something was in my lungs". She was advised by her physician to go to the emergency room, where she underwent laboratory testing and a chest x-ray (results not provided). She was also started on an IV. According to the patient, the discharge diagnosis was "unspecified adverse effect of other drug, medicinal and biological substance". The event subsequently recovered.
Age: 38.0
Sex: F
Vaccine: FLU3
Symptoms: Palpitations, Retching, Swelling face
Clinical narrative: This case was extracted from VAERS via QSCAN on 11 March 2009 (reference number 293833). A 38-year-old female patient received an intramuscular injection of FLUZONE SV 2007-2008 (lot number U2505AA) on 15 October 2007. Approximately five hours post-vaccination, the patient complained of shortness of breath, lightheadedness, a sick feeling in her stomach, and a "racing heart". She experienced a cough, dry heaves, blood-shot eyes with pus, profuse sweating, and shivering. The symptoms continued the next morning, and at that time she also complained of eye and cheek swelling, and lightheadedness. She was unable to take a deep breath, and felt like "something was in my lungs". She was advised by her physician to go to the emergency room, where she underwent laboratory testing and a chest x-ray (results not provided). She was also started on an IV. According to the patient, the discharge diagnosis was "unspecified adverse effect of other drug, medicinal and biological substance". The event subsequently recovered.
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Aphasia, Asthenia, Blood test, Blood test normal, Chest discomfort
Clinical narrative: This serious case was extracted from the VAERS database via QScan on 11 March 2009 (reference number 296645). A 26-year-old pregnant female patient had received a first dose intramuscular injection of Fluzone SV 2007-2008, lot number U2451AA on 01 November 2007 and three hours later, she woke from a nap with a headache, fever 99.8 degrees Fahrenheit, bloodshot eyes, diarrhea was admitted for a TIA workup. Medical records of dates of service 01-07 November 2007 noted the patient was admitted with mental status changes, an episode of slurred speech and headache. Resolved by arrival at the hospital. The patient reported feeling tired that morning numbness and weakness. Physical examination findings were within normal limits. A neurology workup was inconclusive; however the neurology consult felt the patient's speech difficulty was due to her swollen tongue. C/o throat tightness. The patient had an EKG, echocardiogram, carotid dopplers, and blood tests performed with normal findings. A CT scan of the head was negative. It was further noted that the fetus was unaffected and all symptoms resolved. The patient recovered from the event (date of recovery not reported). Documents held by sender: None.
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Computerised tomogram normal, Diarrhoea, Drug exposure during pregnancy, Dysarthria, Echocardiogram
Clinical narrative: This serious case was extracted from the VAERS database via QScan on 11 March 2009 (reference number 296645). A 26-year-old pregnant female patient had received a first dose intramuscular injection of Fluzone SV 2007-2008, lot number U2451AA on 01 November 2007 and three hours later, she woke from a nap with a headache, fever 99.8 degrees Fahrenheit, bloodshot eyes, diarrhea was admitted for a TIA workup. Medical records of dates of service 01-07 November 2007 noted the patient was admitted with mental status changes, an episode of slurred speech and headache. Resolved by arrival at the hospital. The patient reported feeling tired that morning numbness and weakness. Physical examination findings were within normal limits. A neurology workup was inconclusive; however the neurology consult felt the patient's speech difficulty was due to her swollen tongue. C/o throat tightness. The patient had an EKG, echocardiogram, carotid dopplers, and blood tests performed with normal findings. A CT scan of the head was negative. It was further noted that the fetus was unaffected and all symptoms resolved. The patient recovered from the event (date of recovery not reported). Documents held by sender: None.
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Echocardiogram normal, Electrocardiogram, Electrocardiogram normal, Fatigue, Headache
Clinical narrative: This serious case was extracted from the VAERS database via QScan on 11 March 2009 (reference number 296645). A 26-year-old pregnant female patient had received a first dose intramuscular injection of Fluzone SV 2007-2008, lot number U2451AA on 01 November 2007 and three hours later, she woke from a nap with a headache, fever 99.8 degrees Fahrenheit, bloodshot eyes, diarrhea was admitted for a TIA workup. Medical records of dates of service 01-07 November 2007 noted the patient was admitted with mental status changes, an episode of slurred speech and headache. Resolved by arrival at the hospital. The patient reported feeling tired that morning numbness and weakness. Physical examination findings were within normal limits. A neurology workup was inconclusive; however the neurology consult felt the patient's speech difficulty was due to her swollen tongue. C/o throat tightness. The patient had an EKG, echocardiogram, carotid dopplers, and blood tests performed with normal findings. A CT scan of the head was negative. It was further noted that the fetus was unaffected and all symptoms resolved. The patient recovered from the event (date of recovery not reported). Documents held by sender: None.
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Hypoaesthesia, Mental status changes, Ocular hyperaemia, Pyrexia, Swollen tongue
Clinical narrative: This serious case was extracted from the VAERS database via QScan on 11 March 2009 (reference number 296645). A 26-year-old pregnant female patient had received a first dose intramuscular injection of Fluzone SV 2007-2008, lot number U2451AA on 01 November 2007 and three hours later, she woke from a nap with a headache, fever 99.8 degrees Fahrenheit, bloodshot eyes, diarrhea was admitted for a TIA workup. Medical records of dates of service 01-07 November 2007 noted the patient was admitted with mental status changes, an episode of slurred speech and headache. Resolved by arrival at the hospital. The patient reported feeling tired that morning numbness and weakness. Physical examination findings were within normal limits. A neurology workup was inconclusive; however the neurology consult felt the patient's speech difficulty was due to her swollen tongue. C/o throat tightness. The patient had an EKG, echocardiogram, carotid dopplers, and blood tests performed with normal findings. A CT scan of the head was negative. It was further noted that the fetus was unaffected and all symptoms resolved. The patient recovered from the event (date of recovery not reported). Documents held by sender: None.
Age: 26.0
Sex: F
Vaccine: FLU3
Symptoms: Throat tightness, Ultrasound Doppler, Ultrasound Doppler normal
Clinical narrative: This serious case was extracted from the VAERS database via QScan on 11 March 2009 (reference number 296645). A 26-year-old pregnant female patient had received a first dose intramuscular injection of Fluzone SV 2007-2008, lot number U2451AA on 01 November 2007 and three hours later, she woke from a nap with a headache, fever 99.8 degrees Fahrenheit, bloodshot eyes, diarrhea was admitted for a TIA workup. Medical records of dates of service 01-07 November 2007 noted the patient was admitted with mental status changes, an episode of slurred speech and headache. Resolved by arrival at the hospital. The patient reported feeling tired that morning numbness and weakness. Physical examination findings were within normal limits. A neurology workup was inconclusive; however the neurology consult felt the patient's speech difficulty was due to her swollen tongue. C/o throat tightness. The patient had an EKG, echocardiogram, carotid dopplers, and blood tests performed with normal findings. A CT scan of the head was negative. It was further noted that the fetus was unaffected and all symptoms resolved. The patient recovered from the event (date of recovery not reported). Documents held by sender: None.
Age: 40.0
Sex: M
Vaccine: FLU3
Symptoms: Cough, Eye pain, Eye pruritus, Headache, Ocular hyperaemia
Clinical narrative: This case was extracted from the VAERS database via a search of QScan on 11 March 2009 (reference number 297728). A 40 year-old female patient received an intramuscular injection of Fluzone not preservative 2007-2008 (lot number U2457HA) on 05 November 2007. Later that day, she developed a sudden onset of cough, generalized achiness, headache, and red, scratch, painful eyes. The ocular symptoms lasted two days, and the headache resolved after one day. The patient sought medical attention, and all events subsequently recovered.
Age: 40.0
Sex: M
Vaccine: FLU3
Symptoms: Pain
Clinical narrative: This case was extracted from the VAERS database via a search of QScan on 11 March 2009 (reference number 297728). A 40 year-old female patient received an intramuscular injection of Fluzone not preservative 2007-2008 (lot number U2457HA) on 05 November 2007. Later that day, she developed a sudden onset of cough, generalized achiness, headache, and red, scratch, painful eyes. The ocular symptoms lasted two days, and the headache resolved after one day. The patient sought medical attention, and all events subsequently recovered.
Sex: M
Vaccine: FLU3, HEPA, MMR, VARCEL
Symptoms: Abnormal behaviour, Blood culture negative, Chest X-ray normal, Condition aggravated, Conjunctivitis
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 299441). A male patient (age not reported) had received a first dose injection of FLUZONE, lot number UT2460F, a first dose injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB200AA), a first dose injection of MMR, (manufacturer Merck, lot number 1351U), and a first dose injection of VARIVAX, (manufacturer Merck, lot number 0426U) on 22 October 2007. On the day of vaccination, the patient was noted to have had thick eye discharge, but otherwise in good health and meeting developmental milestones. Per parent report, the patient experienced a high fever for several days after vaccination, and displayed rapid and uncontrollable shaking and seizure like episodes that resulted n the patient being hospitalized. He also experienced breathing difficulty, drowsiness and excessive crankiness and crying. According to medical records, the patient had thick eye discharge on the day of vaccination (22 October 2007). He was diagnosed with conjunctivitis and prescribed eye drops. On 31 October 2007, nine days after receiving the vaccines, the patient returned to their physician with vomiting, lethargy, fever, dyspnea, reduced oral intake, and not acting himself x three days. He was diagnosed with viral disease. The patient was admitted to the hospital that same day with fever and upper respiratory infection (URI). According to hospital records for dates of service 31 October 2007 to 01 November 2007, the patient developed a low grade fever (99-100) and cold symptoms five days prior to admission. He also experienced abnormal movements and slow rhythmic body contractions followed by drowsiness. He was sent to day care and continued to have jerky movements and was noted to have a wide based gait when taken to his primary care physician on the day of hospitalization. On the day of admission, he had vomiting and a max temperature of 102. Fluid collection in the right ear was found upon examination. A chest x-ray was normal; stool "guaic" negative; urine and blood C/S (cultures and sensitivity) negative. The final diagnosis was viral syndrome. On 26 November 2007, the patient returned to their physician with purulent discharge from the eyes x 3 days, nasal discharge x 4 days and cough. He was diagnosed with conjunctivitis and otitis media of the right ear and antibiotics were prescribed. The outcome for the event was reported as life-threatening, hospitalized, and emergency room or doctor visit (ER). The patients recovery status was not reported. The events of conjunctivitis infective and conjunctivitis were included in the coding from the VAERS database; however only the event of conjunctivitis was mentioned in the narrative. Documents held by sender: None.